Q301-- Molecular Thyroid Testing

Solicitation 36C25926Q0430 is a request for a five-year, firm-fixed-price Blanket Purchase Agreement (BPA) to provide molecular testing for thyroid specimens for the Rocky Mountain Regional VA Medical Center and VISN 19. The primary objective is to assess cancer risk in cases with indeterminate results, specifically targeting mutation and gene expression analysis such as BRAF and RET/PTC testing. The contractor is responsible for providing all specimen collection and transport materials, ensuring results are reported within 14 days of receipt, and maintaining valid CLIA and College of American Pathologist (CAP) certifications. Performance must adhere to strict biomedical transport regulations, including 42 CFR Part 72, 49 CFR Parts 171 and 173, and IATA Dangerous Goods Regulations. The award will be made on an all-or-nothing basis to the offeror representing the best value, evaluated through a comparative analysis of technical capability, past performance, and price. Quotes must be submitted via email by 8:00 AM MT on September 10, 2026, and must include four distinct volumes: technical capability, past performance with up to two recent references and signed questionnaires, a completed line-item pricing schedule for an estimated 70 cases, and the completed BPA terms. The period of performance spans from September 20, 2026, through September 19, 2031. Invoicing is to be handled electronically through Tungsten, with a requirement for monthly submissions reviewed by the Contracting Officer.